bluebird bio Inc (BLUE.OQ)
BLUE.OQ on NASDAQ Stock Exchange Global Select Market
119.68USD
19 Jun 2019
119.68USD
19 Jun 2019
Change (% chg)
-- (--)
-- (--)
Prev Close
$119.68
$119.68
Open
--
--
Day's High
--
--
Day's Low
--
--
Volume
--
--
Avg. Vol
169,355
169,355
52-wk High
$189.30
$189.30
52-wk Low
$87.64
$87.64
Consensus Recommendations
| Consensus Recommendation | Next Earnings (approx.) | Company Fiscal Year End Month |
Last Updated |
|---|---|---|---|
| Outperform | -3.08 | December | 20 Jun 2019 |
Analyst Recommendations and Revisions
| 1-5 Linear Scale | Current | 1 Month Ago |
2 Month Ago |
3 Month Ago |
|---|---|---|---|---|
| (1) BUY | 7 | 7 | 8 | 8 |
| (2) OUTPERFORM | 8 | 8 | 8 | 8 |
| (3) HOLD | 8 | 9 | 8 | 8 |
| (4) UNDERPERFORM | 0 | 0 | 0 | 0 |
| (5) SELL | 0 | 0 | 0 | 0 |
| No Opinion | 0 | 0 | 0 | 0 |
| Mean Rating | 2.04 | 2.08 | 2.00 | 2.00 |
Consensus Estimates Analysis
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| # of Estimates | Mean | High | Low | 1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-19 | 19 | 10.98 | 19.80 | 0.00 | 9.29 |
| Quarter Ending Sep-19 | 19 | 12.53 | 29.00 | 2.40 | 17.94 |
| Year Ending Dec-19 | 22 | 51.21 | 76.40 | 19.70 | 86.86 |
| Year Ending Dec-20 | 21 | 165.00 | 443.00 | 49.92 | 349.47 |
| Earnings (per share) | |||||
| Quarter Ending Jun-19 | 21 | -3.08 | -2.72 | -3.35 | -2.49 |
| Quarter Ending Sep-19 | 21 | -3.14 | -2.63 | -3.62 | -2.42 |
| Year Ending Dec-19 | 22 | -12.38 | -10.91 | -13.80 | -9.15 |
| Year Ending Dec-20 | 21 | -11.56 | -7.16 | -15.77 | -6.42 |
Historical Surprises
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Estimates vs Actual | Estimate | Actual | Difference | Surprise % |
|---|---|---|---|---|
| SALES (in millions) | ||||
| Quarter Ending Mar-19 | 13.24 | 12.47 | 0.77 | 5.81 |
| Quarter Ending Dec-18 | 8.12 | 19.42 | 11.30 | 139.19 |
| Quarter Ending Sep-18 | 7.51 | 11.53 | 4.02 | 53.55 |
| Quarter Ending Jun-18 | 9.64 | 7.85 | 1.79 | 18.58 |
| Quarter Ending Mar-18 | 5.60 | 15.96 | 10.36 | 185.11 |
| Earnings (per share) | ||||
| Quarter Ending Mar-19 | -2.80 | -2.99 | 0.19 | -6.90 |
| Quarter Ending Dec-18 | -2.87 | -2.72 | 0.15 | -5.22 |
| Quarter Ending Sep-18 | -2.87 | -2.73 | 0.14 | -4.88 |
| Quarter Ending Jun-18 | -2.35 | -2.91 | 0.56 | -24.01 |
| Quarter Ending Mar-18 | -2.07 | -2.31 | 0.24 | -11.70 |
Consensus Estimates Trend
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Current | 1 Week Ago |
1 Month Ago |
2 Month Ago |
1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-19 | 10.98 | 10.98 | 11.59 | 13.75 | 9.29 |
| Quarter Ending Sep-19 | 12.53 | 12.53 | 13.32 | 17.24 | 17.94 |
| Year Ending Dec-19 | 51.21 | 51.21 | 51.63 | 60.86 | 86.86 |
| Year Ending Dec-20 | 165.00 | 165.00 | 164.71 | 193.15 | 349.47 |
| Earnings (per share) | |||||
| Quarter Ending Jun-19 | -3.08 | -3.08 | -3.07 | -2.90 | -2.49 |
| Quarter Ending Sep-19 | -3.14 | -3.14 | -3.13 | -2.96 | -2.42 |
| Year Ending Dec-19 | -12.38 | -12.38 | -12.36 | -11.71 | -9.15 |
| Year Ending Dec-20 | -11.56 | -11.56 | -11.53 | -10.50 | -6.42 |
Estimates Revisions Summary
| Last Week | Last 4 Weeks | |||
|---|---|---|---|---|
| Number Of Revisions: | Up | Down | Up | Down |
| Revenue | ||||
| Quarter Ending Jun-19 | 0 | 0 | 0 | 0 |
| Quarter Ending Sep-19 | 0 | 0 | 0 | 1 |
| Year Ending Dec-19 | 0 | 0 | 1 | 0 |
| Year Ending Dec-20 | 0 | 0 | 0 | 1 |
| Earnings | ||||
| Quarter Ending Jun-19 | 0 | 0 | 0 | 0 |
| Quarter Ending Sep-19 | 0 | 0 | 0 | 0 |
| Year Ending Dec-19 | 0 | 0 | 0 | 1 |
| Year Ending Dec-20 | 0 | 0 | 0 | 1 |
Earnings vs. 
Estimates- UPDATE 1-Bluebird prices gene therapy at 1.58 mln euros over 5 years
- Bluebird prices gene therapy at 1.575 mln euros over five years
- UPDATE 1-EMA panel recommends approval of Bluebird Bio's first gene therapy
- EMA panel recommends approval of Bluebird Bio's first gene therapy
- UPDATE 7-Bristol-Myers to buy Celgene for $74 bln in largest biopharma deal